A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal
blood vessels grow under the macula at the back of the eye, and also leak blood and fluid,
which damages and scars the macula, affecting vision. The current standard of care for
patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor
(anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels.
SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an
anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet
AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of
the drug through the body.